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ABSTRACT 
Objective: Cisapride is a novel prokinetic agent is best candidate for GERD. Cisapride 20 mg can be given thrice in a day given along with Proton 
pump inhibitor. By developing the sustain release formulation of Cisapride, the frequency of both drug can be reduce to once only to obtain good 
therapeutic response.  
Methods: Cisapride SR Tablets were prepared by direct compression technique with HPMC K4M and HPMC K100M polymers. Followed by various 
evaluation tests including in vitro disintegration and dissolution, the formulation was optimized by 32
Results: Results of Preformulation studies of the Cisapride indicate that it has poor flow property and compressibility property. To improve the flow 
and compressibility property, it was beneficial to use the directly compressible grade components in the formulation of tablet. Results of DSC study 
shown that there is no change in drug’s melting peak after the preparation of tablet. Hydrophilic matrix of HPMC K4M and HPMC K100M in combination 
sustained the Cisapride release effectively for more than 12h. The result indicates that the combination of HPMCK4M and HPMCK100M can be 
successfully, On the basis of the preliminary trials in the present study a3
 full factorial designs with drug release kinetic 
analysis, compatibility studies (FTIR) and stability studies. 
2
Conclusion: The prepared formulation of Cisapride sustains release matrix tablet was stable and effective in treatment. 
 full factorial design was employed to study the effect of independent variables, 
i.e. concentration of HPMCK4M(X1) and concentration of HPMCK100M(X2)on dependent variables like% drug release Q2, Q6 and Q10. Drug release is 
also dependent on the size of matrix tablets so, size and surface area was kept constant. Factorial batches F018, F019, F020, and F021 give the f2 value 
75-100. Factorial batch F019 gives the highest f2 value 86.04 and also all the hour’s drug release was within the specified limits.  
Keywords: Cisapride, HPMCK100M, Pregelatinize, HPMCK4M 
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INTRODUCTION 
Gastroesophageal reflux disease (GERD) is one of the most prevalent 
upper gastrointestinal disorders in clinical practice. GERD is a 
chronic disease with relapsing symptoms, and lifelong treatment is 
required in 25% to 50% of patients. The cause of GERD is unknown. 
The Pathophysiology involves contact of the esophagus with noxious 
substances in refluxed gastric juice. Everyone experiences episodes 
of GERD, however, and a cornerstone for the development of GERD 
is that the contact time between noxious substances in gastric juice 
with the esophagus must be of sufficient duration to result in 
damage to the epithelium [1]. Sufficient duration to cause GERD can 
occur in one of two general ways: first, when contact time between 
epithelium and gastric contents is so prolonged that the noxious 
agents in gastric juice overwhelm an otherwise healthy esophageal 
epithelium and second when contact time between epithelium and 
gastric contents is essentially normal, yet still adequate to produce 
damage because of the greater potency to the refluxate or presence 
of defects thins the epithelium [2].  
There are two forms of presentation: in children and in adults. In the 
first case, the symptoms appear during the first months of life and 
improve up to 12-24 mo in 80% of the cases. Since the 1980s, there 
have been major advancements in the medical management of 
gastroesophageal reflux disease (GERD) [3]. The most successful 
therapies have increased acid secretion and volume with H2-
receptor antagonists and especially proton-pump inhibitors. 
Sucralfate, a mucosal protector, had minimal effect on the treatment 
of GERD except in the rare patient with severe ulcerative 
esophagitis. Despite GERD being considered motility disorder, such 
promotility drugs as bethanechol, metoclopramide, and cisapride 
have had marginal efficacy in treating GERD patients except in 
patients with no erosive disease or dyspepsia with associated 
delayed gastric emptying [4]. Through various mechanisms, these 
drugs were reported to increase lower esophageal sphincter (LES) 
pressure and improve acid clearance, but in reality, they did little in 
patients with more severe disease other than improving gastric 
emptying. None of these promotility agents had an apparent effect 
on the major motor mechanism underlying reflux episodes, transient 
lower esophageal sphincter relaxations (TLESRs) [4].  
The diagnosis of gastroparesis may be confirmed by demonstrating 
gastric emptying delay during a 4-hour scintigraphic study [5]. 
Conventional drug therapy requires periodic doses of therapeutic 
agents. These agents are formulated to produce maximum stability, 
activity and bioavailability. For most drugs, conventional methods of 
drug administration are effective, but some drugs are unstable or 
toxic and have narrow therapeutic ranges. Some drugs also possess 
solubility problems. In such cases, a method of continuous 
administration of therapeutic agent is desirable to maintain fixed 
plasma levels [6]. To overcome these problems, controlled drug 
delivery systems were introduced three decades ago. These delivery 
systems have a number of advantages over traditional systems, such 
as improved efficiency, reduced toxicity, and improved patient 
convenience. The main goal of controlled drug delivery systems is to 
improve the effectiveness of drug therapies [7].  
In the present study, objectives are to formulate stable, effective and 
optimum sustained release dosage form using hydrogel polymers, to 
study the effect of different excipients in the formulation, to evaluate 
the prepared sustained release dosage forms and to perform the 
stability studies. 
MATERIALS AND METHODS 
Materials 
Cisapride Hydrochloride (Cadila Healthcare ltd, Ahmedabad), 
Microcrystalline Cellulose (pH 102) (FMC Biopolymer), Hydroxy 
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propyl methyl cellulose K4M (Dow Chemicals, India), Hydroxy 
propyl methyl cellulose K100M (Dow Chemicals, India), 
Pregelatinize Starch (Colorcon Asia Pvt. Ltd., Mumbai, India), 
Colloidal silicon dioxide (Cabot sanmar Ltd), Magnesium Stearate 
(Amishi drugs and Chemicals). 
Instrument 
Electronic weighing balance (Mettler Toledo PG 403-S, Denver 
Instrument), Cage Blender (Shaan Engineering Pvt. Ltd., Ahmedabad, 
India), Bulk Density measurement apparatus (Electrolab, ETD-
1020), “D” Tooling 8 Station Tablet compression machine (Cadmach 
machinery Co., Pvt. Ltd., Ahmedabad, India), Tablet Hardness Tester 
(Monsanto hardness tester, Mumbai), Friability test apparatus 
(Electrolab, Mumbai), Vernier caliper (Mitutoyo, Mumbai), 
Dissolution Test Apparatus (Electrolab, TDT-06T, Mumbai, India), 
UV Spectrophotometer (UV-1700 Double beam Spectrophotometer, 
Shimadzu Kyoto, Japan). 
Characterization of cisapride 
Description: A white to off white crystalline powder. 
Identification: The Infra-Red absorption spectrum of the finely 
ground sample in KBr dispersion compressed into a disc should 
exhibit maxima only at the same wavelengths as that of a similar 
preparation of working standard [8].  
Selection and justification of excipients  
Diluents: In view of the low or medium dose of drug it is essential to 
add bulking agents or diluents to increase the weight of the tablet. 
Microcrystalline Cellulose (Avicel) was selected as diluents. 
Microcrystalline cellulose in combination as diluents gives better 
flowability i.e. both used as diluent in this SR preparation [9, 10].  
Matrix-forming polymers: HPMC which is most widely used 
matrix-forming polymer because of its excellent compatibility, 
multifunctional property and cost effective, HPMC K4M and HPMC 
K100M (10 to 80 %) [11].  
Lubricants: Magnesium Stearate (0.25-4%) and Colloidal silicon 
dioxide (0.25-3%) are widely used as lubricating agent. [12].  
Preformulation study 
Solubility: Freely soluble in water, 0.1N HCl, pH 4.5 Acetate buffer 
and in methanol, Soluble in pH 6.8 Acetate buffer [13]. 
𝐁𝐮𝐥𝐤 𝐝𝐞𝐧𝐬𝐢𝐭𝐲 = Weight of powder/Bulk volume 
𝐓𝐚𝐩𝐩𝐞𝐝 𝐛𝐮𝐥𝐤 𝐝𝐞𝐧𝐬𝐢𝐭𝐲 = Weight of powder/Tapped volume 
𝐂𝐚𝐫𝐫′𝐬 𝐈𝐧𝐝𝐞𝐱 (%) =







Angle of repose 
The diameter of the powder cone was measured and angle of repose 
was calculated using the equation tan 1
2
= h/r. Where, h and r are the 
height and radius of the powder cone, respectively [14]. 
Drug excipients compatibility study 
API and excipients were been thoroughly mixed in predetermined 
ratio given in below table and passed through the 40 # sieve. The 
blend was to be filled in transparent glass vials and were closed with 
gray colored rubber stoppers and further sealed with aluminum seal 
and charged in to stress condition at above condition. Similarly, API 
should also be kept at all conditions as for the samples. Samples 
were withdrawn for analysis within two day of sampling date as per 
the compatibility study plan. Physical observation should be done at 
every week up to 1 mo and DSC studies were carried out to 
determine the compatibility of excipients with the drug [15].  
Analytical method development 
Calibration curve of Cisapride Hydrochloride: Calibration curve 
for Cisapride hydrochloride was taken in 0.1 N HCl [16].  
Preparation of reagents: (i)0.1 N Hydrochloric acid (pH = 1.2):112, 
8.5 ml of concentrated Hydrochloric acid was taken and added to 
1000 ml of water and measured the pH of the solution. (ii) Standard 
(Stock) solution: Cisapride hydrochloride 100 mg was dissolved in 
0.1N HCl and volume was made up to 1000 ml in 100 ml volumetric 
flask. This stock solution was 100 mcg/ml. This Stock solution was 
diluted with 0.1N HCl to make the concentration of 5, 10, 15, 20, 25 
mcg/ml. Absorbance of each solution was measured at 258 nm using 
Shimadzu UV/Visible double beam spectrophotometer by using 0.1N 
hcl [17, 18].  
Formulation of preliminary trials 
Trial batches with HPMC K4M and HPMC K100M 
Formula method of Preparation of Cisapride SR Tablet 
Method 
Cisapride SR Tablets were prepared by direct compression 
technique. Sifting: Drug was passed through 40# sieve. HPMC K4M 
and HPMC K100M were passed through 30# sieve. All the other 
ingredients were passed through 40 # sieve accept Mg Stearate. Mg 
Stearate was passed through 60# sieve [19, 20].  
Mixing and lubrication 
Cisapride, MCC Avicel pH102 was mixed in a blender for 10 min. at 
18 RPM. Add polymer and colloidal silicon dioxide into the above 
mixture and again mix for 10 min. at 18 RPM. Add Mg Stearate into 
above mixture and mixed it for 3 min. at 18 RPM. 
Evaluation  
Uniformity of weight 
The USP-XXIX weight variation test was carry out by weighing 20 
tablets individually, calculating the average weight, comparing the 
individual tablet weight to average weight. The tablet meets USP-
XXIX test if no tablet differs by more than two times of percentage 
deviation USP-XXIX Standards for Weight Variation Test [21, 22].  
Thickness 
Thickness of tablets was determining using a venire caliper. Three 
tablets were evaluated and an average value was calculated. The 
thickness was measure in mm. 
Hardness test 
Hardness was measure using Pfizer hardness tester. For each batch 
ten tablets was test. The force required to break the tablet is 
recorded. The hardness of tablets of each batch was measured in 
kg/cm2. 
Friability test 
Twenty tablets was weighed and placed in the Roche friabilator and 
apparatus was rotate at 25 rpm for 6 min. After revolutions the 
tablets was deducted and weighed again. The percentage friability 
was measured using the formula. 
Uniformity of content 
Amount of the powder equivalent to 10 mg of Cisapride and was 
dissolved in 100 ml of 0.1N HCl pH 1.2, filtered, diluted suitably and 
analyzed for drug content at 227 nm using UV-spectrophotometer. 
In vitro disintegration time 
In vitro disintegration time of three tablets was determined by using 
digital tablet disintegration apparatus. In vitro disintegration test 
was carried out at 37±2 0C in 900 ml 0.1 N HCL pH 6.8 [23]. 
In vitro dissolution study 
In vitro dissolution study of Cisapride was performed using USP 
Type II dissolution apparatus (Paddle type) at 37±0.5 °C and a 
paddle speed of 75 rpm, 900 ml of 0.1 N HCL pH 6.8 was utilized as 
dissolution medium [24, 25]. The temperature of the medium was 
maintained at 37±0.5 °C. Aliquot of dissolution medium (5 ml) was 
withdrawn at specific time intervals (10, 20, 30, 45 min.) and filtered 
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each with (0.45 µm) whatman filter paper. Equal amount of fresh 
dissolution medium was replaced immediately after each 
withdrawal. The amounts of drugs present in each sample were 
determined by a UV-Visible spectrophotometer after Cisapride. 
Dissolution studies were performed in triplicate (n = 3), and 
calculated mean values of cumulative drug release were used to plot 
the release curves [26, 27].  
Formulation and optimization of sustained-release matrix 
tablets by using 32
It is desirable to develop an acceptable pharmaceutical formulation 
in the shortest possible time using the minimum number of man-
hours and raw materials. A statistical model incorporating 
interactive and polynomial terms was used to evaluate the 
responses [28]. A 3
 full factorial designs 
2
Comparison of dissolution profiles by statistical analysis 
 randomized full factorial design was utilized in 
the present study. In this design, two factors were evaluated, each at 
three levels and experimental trials were carried out at all nine 
possible combinations. The factors were selected based on a 
preliminary study [29]. The concentration of HPMC K4M (X1) and 
concentration of HPMC K100M (X2) were selected as independent 
variables. The % drug release at 2, 6 and 8th hours were Q2, Q6 and 
Q8 respectively selected as dependent variables [30, 31].  
The similarity factor (f2) was defined by CDER, FDA and EMEA as 
the “logarithmic reciprocal square root transformation of one plus 
the mean squared difference in percent dissolved between the test 
and the reference products”. Moore and Flanner give the model-
independent mathematical approach for calculating a similarity 
factor f2 for comparison between dissolution profiles of different 
samples. The similarity factor (f2) given by SUPAC guidelines for 
modified release dosage form was used as a basis to compare 
dissolution profile. The dissolution profiles of products were 
compared using f2. The similarity factor is calculated [32].  
Drug release kinetic analysis by using different release model 
of Cisapride HCl sustained release matrix tablet 
To know the mechanism of drug release from these formulations, 
the data were treated according to first-order (log cumulative 
percentage of drug remaining vs. time), Higuchi’s118 (cumulative 
percentage of drug released vs. square root of time), and Korsmeyer 
et al.’s119 (log cumulative percentage of drug released vs. log time) 
equations along with zero-order (cumulative amount of drug 
released vs. time) pattern the results shown below. The in vitro 
release profiles of the drug from all the formulations could be best 
expressed by Higuchi’s equation, as the plots showed high linearity 
(R2 = 0.9898, table 5.33). To confirm the diffusion mechanism, the 
data were fit into Korsmeyer-Peppas’s equation. The formulations 
F019 showed good linearity (R2: 0.9942), with slope (n) values 
ranging from 0.665, indicating that diffusion is the dominant 
mechanism of drug release with these formulations [33]. This n 
value, however, appears to indicate a coupling of diffusion and 
erosion mechanisms so-called anomalous diffusion. The relative 
complexity of this formulation and its components may indicate that 
the drug release is controlled by more than one process. From the 
above data analysis by using the different model the Korsemeyer 
model was a good fit with a linearity value 0.9942 [34].  
Stability study 
Formulation was placed for stability study at 40̊ C and 75% RH for 1 
mo. Sample was collected at every week interval and evaluated for 
dissolution in 0.1N HCl, USP-II paddle apparatus, 50 rpm. f2 value 
was applied to stability study to show the effect of storage on in vitro 
drug release of the formulation [35].  
RESULTS AND DISCUSSION 
Identification of drug 
Melting point 
The observed melting point of Cisapride was 110-113 °C. Melting 
point of Cisapride was found to be in the range of 113 °C as reported 
in the literature, thus indicating the purity of the drug sample. 
Infrared spectroscopy of drug 
Observed characteristics were N-H stretching at 3400 cm1, CH 
alkane stretching at 2926 cm1, CO-NH stretching (C=0) at 1640 cm1, 
NH bending at 1425 cm1 and CN aromatic amine at1243 cm1
 
 as 
shown in fig. 1. 
 
Fig. 1: FTIR of cisapride 
 
Infrared spectroscopy drug and excipient 
IR spectrum of, physical mixture of Cisapride+MCC+HPMC 
K100M+Pregelatinize Starch and Drug+Colloidal Siliconn Dioxide+Mg-
Stearate are shown in fig. 2 and 3. From IR spectra of drug and 
physical mixture, no significant change in peak pattern was observed. 
Hence, it was concluded that absence of drug excipients interaction 
and drug was compatible with excipients used in the present work. 
  
 
Fig. 2: Drug+MCC+HPMC K100M+pregelatinize starch 
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Fig. 3: Drug+colloidal siliconn dioxide+Mg-stearate 
 
Drug excipients compatibility study 
Drug excipients compatibility study was done with Drug: MCC, Drug: 
Pregelatinize Starch, Drug: Methocel K100M at (1:1) ratio and Drug: 
Colloidal Silicon Dioxide, Drug: Mg Stearate at (1:0.25) followed by 
Drug+MCC+Pregelatinize Starch+HPMC K100M+Colloidal silicon 
Dioxide+Mg-Stearate propositional mixture at 25 °C °±2 
°C/60%RH±5% RH and 40 °C±2 °C/75%RH±5% RH for 4 w 
duration. 
DSC study 
From the DSC Study results shown with physical observation, it was 
concluded that there was no significant Drug-Excipient interaction 
was observed. The results of DSC study shown that there is no 
change in drug’s melting peak after the preparation of tablet. So we 
can conclude that drug and other Excipients are compatible which 
each other [36].  
Preformulation study results 
From the Results of Preformulation studies of the API, It was 
concluded that Cisapride has poor flow property and compressibility 
property. So, to improve the flow and compressibility property, it 
was beneficial to use the directly compressible grade components in 
the formulation of the tablet [37]. 
Analytical method development 
UV spectroscopy 
As shown in table 1, Stock solution (1 mg/ml) of drug was prepared 
in water. This solution was appropriately diluted with water to 
obtain a concentration of 200 µg/ml. The solution was kept in a 
silica cuvette 10 mm. The UV spectrum was recorded in the range 
200-400 nm on Shimadzu 2501 PC double beam spectrophotometer 
at 1 nm, slit width [38]. 
  
Table 1: Preformulation study of cisapride 
Drug Angle of repose ( °) Loose bulk density (g/ml) Tapped bulk density (g/ml) Carr’s index (%) Hausner’s ratio 
Cisapride 27.34±0.52 0.375±0.05 0.516±0.03 27.32±0.4 1.37±0.04 
n = 3, mean±SD 
 
 
Fig. 4: Calibration curve of cisapridein 0.1N HCl 
 
Table 2: Absorbance at different concentrations of cisapride 
S. No. Concentration (mcg/ml) Absorbance Avg. Absorbance ±SD a 
A1 A2 A3 
1 0 0 0 0 0 
2 5 0.198 0.186 0.189 0.191±0.003 
3 10 0.351 0.359 0.352 0.354±0.002 
4 15 0.534 0.530 0.526 0.530±0.005 
5 20 0.688 0.687 0.686 0.687±0.003 
6 25 0.843 0.851 0.850 0.848±0.005 
amean±SD, n = 3. 
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Formulation of preliminary trials 
Trial batches with HPMC K4M and HPMC K100M 
Table 2: Formula of trial batches F001 to F005 
Trial F001 F002 F003 F004 F005 
Cisapride 20.00 20.00 20.00 20.00 20.00 
MCC(Avicel PH 102) 35.00 25.00 35.00 25.00 30.00 
HPMC K4M 30.00 40.00 … … … 
HPMC K100M … … 30.00 40.00 35.00 
Colloidal SiliconDioxide 6.00 6.00 6.00 6.00 6.00 
MagnesiumStearate 4.00 4.00 4.00 4.00 4.00 
Talc 5.00 5.00 5.00 5.00 5.00 
Total 100.00 100.00 100.00 100.00 100.00 
MCC: Microcrystalline cellulose, HPMC: hydroxypropyl methylcellulose 
 
The results of angle of repose and compressibility index ranged from 
23.31±0.42 to 25.14±0.32 and 11.83±0.22 to 15.28±0.40, 
respectively. The results of Hausner’s ratio and blend uniformity 
ranged from 1.13±0.05 to 1.18±0.04 and 98.23±0.15 to 99.21±0.39, 
respectively [1]. The results of the angle of repose (<30) indicate 
good flow properties of the powder. This was further supported by 
lower compressibility index values. Generally, compressibility index 
values up to 15% results in good to excellent flow properties. 
Evaluation of tablets 
Hardness of the prepared tablets was found in the range of 6-8 kP. 
All the tablet formulations showed acceptable pharmaco technical 
properties and complied with the in-house specifications for weight 
variation, drug content, hardness, and friability. 
In vitro release study 
The results of in vitro dissolution study of trial batches F001 to F005 
which was taken singal polymer like HPMC K4M and HPMC K100M. 
From the results as shown in fig. 5, concluded that by using single 
polymer like HPMC K4M and HPMC K100M, release profile was not 
desirable. However, among these formulations, F004 and F005 were 
selected for further development because they shown comparatively 
less deviation from the targeted release profile. So, further study 
was planned by using some release retardant polymer like Ethyl 
cellulose and Pregelatinize starch in different concentrations [40].  
Trials with ethyl cellulose and pregelatinize starch in 
combination with HPMC K100M 
The results with release retardant polymer in combination with 
HPMC K100M indicate that the formulations still need modification 
to get desired release profile. Based on this study, it was proposed to 
use the combination of both water-soluble matrix-forming polymer 
HPMC K4M and HPMC K100M in proper concentration. 
Trials with the combination of HPMC K4M and HPMC K100M 
Hydrophilic matrix of HPMC K4M and HPMC K100M in combination 
sustained the Cisapride release effectively for more than 12 h. From 
the result, it concluded that the combination of HPMC K4M and HPMC 
K100M can be successfully utilized to create desire release profile 
similar to the targeted release profile in further study. On the basis of 
the preliminary trials in the present investigation, a 32 full factorial 
design was applied to study the effect of independent variables, i.e. 
concentration of HPMC K4M (X1) and concentration of HPMC K100M 
(X2) on dependent variables like %drug release Q2, Q6 and Q10. 
 
 
Fig. 5: Comparative dissolution profile of Trial F01 to F013 and Innovator 
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Formulation and optimization of sustained-release matrix 
tablets by using 32 full factorial designs: 32 full factorial design 
layout of Cisapride sustained release matrix tablet of selected 
formulations.
 
Table 3: Formula of factorial batches 
Trial F014 F015 F016 F017 F018 F019 F020 F021 F022 
Cisapride 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 
MCC (Avicel PH 102) 30.00 25.00 20.00 25.00 20.00 15.00 20.00 15.00 10.00 
HPMC K4M DC Grade 15.00 15.00 15.00 20.00 20.00 20.00 25.00 25.00 25.00 
HPMC K100M DC Grade 20.00 25.00 30.00 20.00 25.00 30.00 20.00 25.00 30.00 
Colloidal silicon dioxide 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 
Magnesium stearate 4.00 4.00 4.00 4.00 4.00 4.00 4.00 4.00 4.00 
Talc 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 
Total 100 100 100 100 100 100 100 100 100 
MCC: Microcrystalline cellulose, HPMC: hydroxypropyl methylcellulose 
 
In vitro drug release 
The result of regression analysis showed that all the co-efficient bear 
a negative sign, which indicates that by increasing the concentration 
of both the polymers the drug release was sustained. Drug release at 
2nd hr (Q2) gives a correlation co-efficient 0.9907. 
The P-value for variable X1 and X2 were 0.0006 and 0.002 
respectively (P<0.05), it indicate that both variable shown 
significant effect on drug release and combination co-efficient was 
negative but the P value was not less than 0.05, which indicates that 
combination of an independent variable did not show significant 
effect at 2nd h release  
Q2 = 37.644 − 5.417X1 − 3.25X2 − 0.7X1X2 − 2.017X2 − 0.817X2 
Drug release at 8h (Q8) has less linearity compared to Q2 with a 
correlation coefficient 0.9849. The P-value for variable X1 and X2 
were 0.013 and 0.007 (P<0.05), it indicate that both variable has a 
significant effect on the drug release at 6h. and the combination co-
efficient was negative but the P-value was not less than 0.05 so, we 
say that the combination of independent variable was not giving the 
significant effect at 6h release. The co-efficient of X1 and X2 were 
negative indicate that when the concentration of both the variable 
increase than drug release was decreased. 
Q8 = 72.367 − 8.05X1 − 4.4X2 − 2.275X1X2 − 3.75X12 − 0.11X2 
Drug release at 10h (Q10) has the P-value for variable X1, X2 and 
X1X2 were 0.002, 0.024, 0.035 respectively(P<0.05), it indicate that 
both variable has a significant effect and also the combination of 
variable has a significant effect on drug release at 10h. The co-
efficient of X1 and X2 were negative indicate that when the 
concentration of both the variable increase than drug release was 
decreased. 
Q12 = 90.844 − 5.8X1 − 2.633X2 − 2.8X1X2 − 0.26X12 − 2.467X2 
The Q2, Q8, and Q10 for all the batches F014 to F022 varied from 43.2 
% to 25.1%, 79.4% to 52.9%, and 94.3% to 75.8% with correlation 
coefficient as 0.9907, 0.9849 and 0.9760 respectively. The dissolution 
profile of all the formulation batches prepared by using 32 factorial 
designs was compared by similarity factor f2 value. Factorial batches 
F018, F019, F020 and F021 give the f2 value 75.85, 86.04, 82.81, 74.71 
respectively. In factorial batch F018 the drug release obtained was 
57.1%, 70.8% and 80.1% at 4h, 6h, and 8h, respectively, was faster 
than the targeted release profile. In trial batch F020, f2 
Value was above 75 but 4th hr release was outside the specified 
range. Trial batch F021 also has the f2 value nearer 75, but 4h 
release was slower than we required. Trial batch F019 the highest f2 
value 86.04 was obtained and also, all the hour’s drug release was 
within the specified range. Based on the f2 value and targeted 
release profile, the suggested optimized batch was F019. 
CONCLUSION 
Factorial batches F018, F019, F020, and F021 give the f2 value 75-
100. Factorial batch F019 gives the highest f2 value 86.04 and also 
all the hour’s drug release was within the specified range. Based on 
the f2 value and targeted release profile, the optimized batch was 
F019. The co-efficient of X1 and X2 were negative indicate that when 
the concentration of both the variables increase than drug release 
was decrease. From the result of 32 full factorial design and 
regression analysis for Cisapride Sustained release matrix tablet, it 
was concluded that factorial batch F019 taken with the combination 
of 7.5% HPMC K4M and 25% HPMC K100M give drug release 
comparable to the targeted release profile with f2 value 86.04.  
In the present study, to check the reproducibility, batch was taken 
with larger batch size and carried out accelerated stability study. 
From the result, it concluded that the reproducible batch taken with 
7.5% HPMC K4M and 25% HPMC K100M has good reproducibility. 
The result of regression analysis showed that all the co-efficient bear 
a negative sign, which indicates that by increasing the concentration 
of both the polymers the drug release was sustained. The drug 
release was followed the Korsemeyer model and which indicate a 
coupling of diffusion and erosion mechanisms, so-called anomalous 
diffusion. From the stability result we said that there was no change 
in the formulation after 1 mo accelerated stability study. The 
prepared formulation of the Cisapride sustain release matrix tablet 
was stable. 
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